Whole blood was obtained for mutation analysis in IRD patients who had forms of RP for which genetic testing was available; genetic testing was not performed on RP cases without a history of Ashkenazi Jewish descent or a family history of consanguinity (patients 40023, 30015, 40031, 40043, 40046, 40041, 40037, 40039, 40047, 40058, 40026, and 40060). Five patients were tested through the eyeGENE consortium for molecular analysis of genes associated with x-linked RP (patients 40015 and 40049), with autosomal dominant RP (patients 40073 and 10048), and with choroideremia (patient 40028); no disease-causing mutations were identified in 10048. Genetic testing for mutations associated with Ashkenazi heritage for patient 40030 was performed through the Carver Nonprofit Genetic Testing Laboratory (Iowa City, IA, USA); no disease-causing mutations were identified in the
DHDDS,
LCA5,
MAK,
PCDH15, or
CLRN1 genes. Genetic testing was performed through a research protocol (Radha Ayyagari, PhD, Project #081869, University of California San Diego, San Diego, CA, USA) using whole-exome sequencing
36,37 in families with autosomal recessive RP from a consanguineous pedigree (patient 40032). Mutation analysis of the
CLRN1 gene in 30007 was carried out by sequencing the coding region. Patients' genomic DNA was extracted from whole blood samples with Puregene Genomic DNA PurificationKit (Gentra Systems, Minneapolis, MN, USA) or from saliva with Oragene kits (DNA Genotek, Inc., ON, Canada). The three exons and the exon-intron boundaries of the
CLRN1 main splice variant (GenBank accession NM_174878) were screened for mutations by genomic sequencing, as previously described.
38,39